VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (TSX Venture: MBI), a biotechnology company developing genetic biomarkers to improve screening, diagnosis, prognosis and treatment decisions for patients suffering from cancer and cardiovascular disease, today announced that Dr. Nathan Yoganathan, MBI's founder, President and Chief Scientific Officer has transitioned to a senior advisory role as Chief Scientific Advisor. Dr. Bradley McLean, a senior scientist with MBI, was appointed Chief Scientific Officer.

"Nathan advised the board of directors that he wished to be actively involved in Med BioGene but desired to transition from a day to day operational role to a senior advisory role. We respect Nathan's decision and are pleased that he will continue to work with the company and allow us to continue to leverage his skills and experience. Nathan has played a crucial role in founding and developing Med BioGene as an emerging biotechnology company with world class research collaborations, in particular with Duke University and the University of Ottawa Heart Institute" said Erinn Broshko, Chief Executive Officer of MBI.

"Brad has proven research and operational experience and we expect him to execute at the highest level as Chief Scientific Officer" concluded Mr. Broshko.

Prior to joining MBI in early 2007, Dr. McLean led the research and development of a prodrug at Twinstrand Therapeutics Inc., a clinical stage biotechnology company, to specifically target late-stage prostate cancer and the development of a chemically modified (PEGylated) variant of Twinstrand’s lead cancer therapeutic. Prior to joining Twinstrand, Dr. McLean was a post-doctoral fellow at the British Columbia Research Institute for Children's and Women's Health and InphoGene BioCommunications Inc. a private genomics and bioinformatics company, undertaking research into Ewings sarcoma, a rare pediatric cancer. Dr. McLean holds a B.Sc. (Hons.) and an M.Sc. from Queen’s University and a Ph.D. from the University of British Columbia.

About Med BioGene

MBI is a biotechnology company with advanced research and development in gene expression technology. MBI intends to utilize its expertise in gene expression to identifying those genes, known as "biomarkers," which mark the presence of various diseases. These biomarkers will be used as an effective tool for accurate and rapid screening and diagnosis and to unlock innovation in therapeutic development and treatment. With a robust set of qualified biomarkers, disease screening and diagnosis will be quicker, less invasive and more accurate and the safety of new therapeutics will be increased, drug products will get to patients in less time and treatment decisions will be more informed.

MBI is currently focused on developing and validating biomarkers in respect of cancer and cardiovascular disease through its Gene Expression Profiling System^TM.

For corporate information, please contact:

Erinn B. Broshko
Chief Executive Officer
(604) 306-4969
ebroshko@medbiogene.com
www.medbiogene.com

For investor relations information, please contact:

The Howard Group Inc.
(888) 221-0915
info@howardgroupinc.com
www.howardgroupinc.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Certain statements in this press release contain forward-looking information under applicable Canadian securities legislation.  Words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but are not limited to, those with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. These forward-looking statements or information are only predictions based upon MBI’s current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI’s actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speaks only as of the date of this press release. Our forwardlooking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments MBI may make. All forward-looking information is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.